background: It is becoming increasingly evident that the eutopic endometrium of women with endometriosis shows certain genetic alterations which are not found in the endometrium of disease-free women. The aim of the study was to compare the expression level of mammalian target of rapamycin (mTOR) tumor suppressor and oncogene-related genes in the endometrium of women with and without endometriosis as well as in ovarian endometriosis.
Introduction
The pathogenesis of endometriosis, a benign gynaecological disorder defined as the presence of endometrial glandular and stromal cells outside the uterine cavity, still remains controversial despite extensive research. The most widely accepted theory stipulates that during menstruation there is a reflux of endometrial tissue via the fallopian tubes into the peritoneal cavity where it can implant (Sampson, 1925) . Retrograde menstruation is, however, a common phenomenon so it is still unknown why endometriosis affects not more than about 10% of the female population in their reproductive years.
It is becoming increasingly evident that the primary defect in endometriosis can be located in the eutopic endometrium. Abnormalities inherent to the eutopic endometrium, which are not found in the endometrium of disease-free-women, might therefore contribute to ectopic growth outside the uterine cavity (Ulukus et al., 2006) . Different characteristics of eutopic endometrium of women with endometriosis, such as aberrant production of cytokines, growth and angiogenic factors as well as specific cancer-related genes, are believed to contribute to the establishment and maintenance of this disease. Since evidence for a relationship between cancer and endometriosis is mounting, especially regarding endometriotic and clear-cell ovarian carcinomas, it appears feasible to hypothesize that some changes in the expression pattern of tumor suppressor and oncogenes occur in eutopic endometrium which could predispose to overgrowth and survival of endometrial foci outside the uterus (Ness, 2003; Vigano et al., 2006) . This is supported by molecular genetic evidence, and abnormalities of such proto-oncogenes and tumor suppressor genes (TSGs) as KRAS, PTEN and TP53, or more recently mammalian target of rapamycin (mTOR), were found to be associated with endometriosis (Yagyu et al., 2006) .
Gene product of mTOR is a conserved seronine/threonine kinase that regulates cell growth and metabolism by modulating many processes, including cell cycle progression, translation control, ribosome biogenesis or autophagy. It is becoming increasingly evident that precancerous lesions activate the mTOR pathway and its upstream and downstream signaling components, predominantly, key TSGs and oncogenes, which are frequently altered in a number of human tumors (Sabatini, 2006) . mTOR enhances translation initiation in part by phosphorylating two major targets: the 4E-BP1 (inhibitory 4E-binding protein) family of proteins and ribosomal protein S6 kinases (for example oncogene S6K1). By phosphorylating the 4E-BP1, a well established tumor suppressor, mTOR represses its capacity to inhibit the mRNA cap-binding protein transcription factor eIF4E-a known potent oncogene. When eIF4E is released, translation can begin. Translation is also prompted by activated S6K1, which co-operates to regulate gene expression and translation processes, particularly the translation of proteins encoded by 5'terminal oligopyrimide (5'TOP) genes. Most 5'TOP genes are regulators of protein synthesis and can act as protooncogenes (Sabatini, 2006) . In addition to its role in promoting protein synthesis, S6K1 represses the phosphatidylinositol 3-kinase (PI3K) related pathways, whereas different growth factors, mitogens and hormones activate PI3K signaling and consequently mTOR (Shaw and Cantley, 2006) . PI3K is a heterodimer that is composed of a p85 regulatory and a p110 catalytic subunit (encoded by PIK3CA). When activated, PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate to generate phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 binds and activates such kinases as the oncogene AKT.
On the other hand, activation of AKT is physiologically prevented by a gene product of tumor suppressor PTEN (phosphatase and tensin homologue deleted from chromosome 10), a phosphatase that removes the phosphate attached by PI3K from PIP3. AKT protein is also an indirect positive regulator of mTOR through the phosphorylation and inactivation of mTOR inhibitors, such as protein products of the TSC1 and TSC2 genes-well established tumor suppressors (Wullschleger et al., 2006) .
The TSC1 -TSC2 protein complex acts as a GTPase-activating protein and inhibits the small G-protein called Ras Homolog Enriched in Brain (RHEB)-a potent protooncogene, expression of which is elevated in many tumor cells (Basso et al., 2005) . TSC1 -TSC2 and RHEB also have important roles in the activation of mTOR that occurs when cells lose tumor suppressors, such as PTEN, neurofibromatosis 1 (NF1), LKB1 (also known as serine -threonine kinase 11) or P53 (Sabatini, 2006) .
One of the first identified tumor-suppressor genes was NF1, which encodes a GnRH-associated protein for Rat Sarcoma (RAS). Loss of NF1 results in the accumulation of RAS and prolonged activation of RAS can occur in tumors by mechanisms that do not necessarily involve mutations (Shaw and Cantley, 2006) .
LKB1 gene is inactivated in Peutz-Jeghers syndrome (characterized by the development of polyps in the gastrointestinal tract) and is crucial in inhibiting the mTOR pathway in response to energy starvation, as LKB1 protein is necessary to protect the cell from death triggered by stress (Inoki et al., 2005a, b) . One of the consequences of energy deprivation is an induction of autophagy and the inhibition of this process may be associated with tumor development (Gozuacik and Kimchi, 2004) . For instance, loss of tumor suppressor BECLIN1 (BECN1) reduces autophagic cell death (Gozuacik and Kimchi, 2004) .
In our study we aimed to investigate levels of gene expression of the above described group of TSGs and oncogenes functionally related to mTOR pathway ( Fig. 1) (Wullschleger et al., 2006) . Accumulated evidence suggests that there are some pathways in common between cancer and endometriosis, and we assumed that at least at the level of expression of some key components of the pathway, it may be informative to study their role in the endometrium of women with endometriosis.
Materials and Methods

Patients and sample collection
A total of 81 patients were recruited in the study. Endometrial samples were obtained from regularly menstruating premenopausal women aged 20 -35 years undergoing diagnostic or surgical laparoscopy for nonmalignant ovarian lesions. Patients with endometriosis (Group I, n ¼ 40), stages from I to IV (I-n ¼ 11, II-n ¼ 4, III-n ¼ 18, IV-n ¼ 7), were diagnosed by laparoscopic findings according to the Revised American Fertility Society classification of endometriosis (1997) and each case was confirmed by histopathology.
As a control (Group II, n ¼ 41) we used endometrial tissue from patients with no endometriosis visible during laparoscopy. Twenty-seven of these women were infertile and 14 were fertile with benign ovarian cysts.
Patients with autoimmune disease, pelvic inflammatory disease, adenomyosis, dysfunctional uterine bleeding and those who took non-steroidal anti-inflammatory drugs, GnRH agonists or steroids during the previous 3 months were excluded.
Endometrial samples were collected by Pipelle suction in the operating room before the laparoscopic procedure and endometriosis samples were taken during laparoscopy. Endometrial tissue samples were classified by histological dating according to the method of Noyes et al. (1950) and only patients in the proliferative phase (days 8 -12) of the cycle were included in the study.
Among all the patients with endometriosis, in whom eutopic endometrium was collected, only in 17 cases (with moderate and severe disease) were we able to properly collect endometriotic samples. As 14 of these 17 samples were endometrial cysts, we therefore chose only ovarian endometriosis for further analysis to make the subgroup sufficiently homogeneous for subsequent statistical analysis. All of the endometriotic cysts were at least 3 cm in diameter and contained a granular epithelium surrounded by stromal tissue. The presence of these features was sufficient to meet the criteria for histopathological diagnosis of endometriosis. We confirmed microscopically that cyst samples were not contaminated with normal ovarian tissues and only pieces taken solely from those samples were used for RNA isolation. The study protocol was approved by the Local Ethical Committee of Medical University of Bialystok, Poland, and informed consent was obtained from each patient.
Sample processing
A piece of each tissue was divided into two and one half placed in buffered formalin for histopathological studies or RNA later (Sigma Aldrich, Poland) Tumor suppressors and oncogenes in endometriosis for molecular analysis. The tissue for RNA extraction was stored for 24 h at þ48C and then stored at 2808C. RNA extraction was carried out using a Macherley-Nagel (Duren, Germany) isolation kit (NucleoSpin RNA) according to manufacturer's protocol. RNA concentration and quality was determined using the NanoDrop spectrophotometer (Kisker, Steinfurt, Germany) and the Agilent Bioanalyzer 2100 (Agilent Technologies, Perlan, Poland). Two micrograms of total RNA with a RNA Integrity Number (RIN value) of at least seven, with clearly visible bands, was converted to single stranded complementary DNA (cDNA) using HighCapacity cDNA Archive Kit according to the manufacturer's protocol (Applied Biosystems, Applera, Poland).
A TaqMan real-time PCR low density arrays
The TaqMan Low-Density Array is a custom designed 16 gene expression assay (Applied Biosystems, Applera, Poland) preconfigured in a 384-well format and spotted on a micro fluidic card (three replicates per assay). The Gene Expression Micro Fluidic Card contains eight sample-loading ports, each connected by a micro channel to 48 miniature reaction chambers (16 Â 3) for a total of eight samples per card (Fig. 2) .
The assay IDs are: NF1-Hs00169714_m1, RHEB-Hs00356729_g1, mTOR-Hs00234522_m1, PTEN-Hs00829813_s1, TSC1-Hs00184423_m1, TSC2-Hs00241068_m1, KRAS-Hs00270666_m1, S6K1-Hs00177357_m1, TP53-Hs00153340_m1, EIF4E-Hs00908915_g1, LKB1-Hs00176092_m1, PIK3CA-Hs00180679_m1, BECN1-Hs00186838_m1, 4EBP1-Hs00607050_m1, AKT1-Hs00178289_m1. The expression of the target genes was normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase (GADPH, assay ID was: hs99999905_m1).
Hundred microliter of each cDNA samples were added to an equal volume of 2ÂTaqMan Universal PCR Master Mix with uracil-DNA glycosylase (Applied Biosystems, Applera, Poland) and after brief mixing and centrifugation, the mixture was transferred into one of the eight loading ports on a micro fluidic card. The cards were centrifuged in a Sorvall Legend TM centrifuge (Kendro Scientific, Asheville, USA) for 1 min at 306g to distribute the samples from the loading port into each well. Following centrifugation, the cards were sealed with a TaqMan low-density array sealer (Applied Biosystems, Applera, Poland) to prevent crosscontamination. Each card was placed in the card sample block of an ABI Prismw 7900HT sequence detection system (Applied Biosystems, Applera, Poland) and the PCR amplifications were run. Thermal cycling conditions were as follows: 2 min at 508C to activate uracil-DNA glycosylase, 10 min at 94.58C (activation) and 40 cycles of denaturation at 978C for 30 s, and annealing and extension at 59.78C for 1 min.
Gene expression values were calculated using the DDC t method, where one sample was designated the calibrator, through which all other samples were analyzed (Livak and Schmittgen, 2001) . Briefly, DC t represents the threshold cycle of the target minus that of GADPH, and DDC t represents the DC t of each target minus that of the calibrator. Relative quantities (RQ) were determined using the equation: RQ ¼ 2 2DDCt . For the calibrator sample, i.e. reference RNA from normal endometrium (Ambion, Applera, Poland), the equation is RQ ¼ 2
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, which is 1, therefore, every other sample is expressed relative to this. AKT and mTOR are considered as central factors upon which diverse oncogenic signals may converge. TK indicates tyrosine kinase; PtdIns(4,5)P 2 , phosphatidylinositol-4,5 bisphosphate; PtdIns(3,4,5)P 3 , phosphatidylinositol-3,4,5-trisphosphate; RSK, ribosomal protein S6 kinase. Remaining abbreviations and detailed description are explained in the Introduction section.
Immunohistochemistry
The resected specimen was fixed in 4% buffered formaldehyde solution for 24 h and embedded in paraffin blocks at 568C. For routine histology, hematoxylin-eosin staining was performed. For the immunohistochemical studies, a representative section from the resected specimen was selected. The section was deparaffinized in xylenes and rehydrated through graded alcohols. For antigenic recovery, the material was immersed in citrate buffer, pH 6, and placed in a microwave oven for 20 min. The material was then cooled to room temperature for at least 15 min. Endogenous peroxidase activity was blocked by Peroxidase Blocking Reagent for 5 min at room temperature. After rinsing in phosphate-buffered saline ph 7.4 (4E-BP1) and Tris (AKT1), the sections were incubated with primary antibodies for 24 h at 48C. AKT1 (R&D Systems, Biokom, Poland) and 4EBP1 (Santa Cruz Biotechnology, Bergheimer, Germany) were assessed using monoclonal mouse antibodies, namely: anti-human AKT1 from R&D Systems (clone 302407) which was diluted 1:62 in Tris buffer ph7.4 and 4E-BP1, diluted 1:275 in serum block, from Santa Cruz Biotechnology (clone 11G12C11).
Sections were then incubated with biotinylated secondary antibody at room temperature for 30 min (4E-BP1) and 60 min (AKT1). Afterwards sections were incubated with ABC solution (Santa Cruz Biotechnology and R&D Systems) at room temperature for 30 min, followed by diaminobenzidine tetrachloride solution at room temperature for 10 min, and counterstained in Mayer's haematoxylin. Sections were subsequently dehydrated, transferred to xylene and eventually mounted in a resinous mountant. The expression of protein was evaluated by observation using light microscopy (Olympus CX21). Negative controls were performed by omitting the primary antibody whereas sections of endometrioid endometrial carcinomas were used as a positive controls.
Statistical analysis
All the calculations have been carried out using Microsoft Excel spreadsheets and STATISTICA, StatSoft, Inc. Ver. 7.1. statistical package (data analysis software system). Data were expressed as arithmetic mean and median, and measures of variation were SD and range. The normality of distribution of the variables and variance equality of a studied feature in groups was tested by the use of appropriate Shapiro-Wilk's test and a variance equality test. Although comparing two groups for quantitative data, Mann -Whitney-Wicoxon's test was used owing to the non-normal distribution of the tested variables. In order to reduce the type I error rate in many comparisons of pairs, Kruskal -Wallis method and multiple comparisons post-hoc tests were subsequently used. In every case P-values for Mann-Whitney-Wilcoxon and Kruskal -Wallis with multiple comparisons post-hoc tests were concordant. In order to evaluate the strength, direction and significance of interrelationships between variables we used Pearson's coefficient of linear correlation, and for non-parametric data we used Spearman's coefficient of correlation between ranks. A P , 0.05 was considered statistically significant.
Results
Clinical characteristics of patients are presented in Table I and detailed RQ as well as P-values are shown in Table II .
Of the 15 genes studied we found significantly higher 4EPB1 and AKT1 mRNA levels in the eutopic endometrium of women with endometriosis as compared with the control group. When we compared mRNA levels between eutopic endometrium and ovarian endometriosis from the same patients (successful collection in 14 cases), we found that the expression level of all but three genes (i.e. TSC2, AKT1 and 4EBP1) was significantly higher in the endometriosis lesions from the ovary. In the case of 4EBP1, mRNA levels were significantly higher in the eutopic endometrium than in the ovarian endometriosis and no differences were observed as to TSC2 and AKT1 (Table II) .
In the remaining 26 patients with endometriosis we were unable to collect tissue with sufficient quality and quantity of RNA, as assessed by RIN value. Since it is commonly accepted that RIN values of ,7, Tumor suppressors and oncogenes in endometriosis with barely visible bands, are inappropriate for further processing and analysis in qualitative PCR, we decided to choose samples with RIN .
7.
We attempted to analyze differences and determine correlations for median gene expression between subgroups of patients allocated according to cycle day of endometrium collection (day 8-12). The Spearman test showed that in the endometriosis group of patients there is an inverse correlation between expression of TP53 (Fig. 3A) as well as PTEN (Fig. 3B ) and day of the cycle i.e. R ¼ 20.5922, P ¼ 0.00005 and R ¼ 20.64, P ¼ 0.01, respectively. In the control group we also found an inverse correlation between expression of PTEN (R ¼ 20.47, P ¼ 0.002), 4EBP1 (R ¼ 20.42, P ¼ 0.007) and AKT1 (R ¼ 20.39, P ¼ 0.01) and cycle day (not shown). The median RQ values for all genes according to day of the cycle are presented in Table III .
We found that expression of 4EBP1 i.e. 7.92 (1.24-47.94) and AKT1 i.e. 10.58 (1.3 -95.85) in the early stages of endometriosis (I and II) is significantly higher (P ¼ 0.02 for 4EBP1 and P ¼ 0.01 for AKT1) than in moderate and severe disease (III and IV), respectively, 2.24 (0.55-39.74) and 1.92 (0.51-57.2). Table IV presents comparison of median RQ values of all studied genes in minimal and mild versus moderate and severe stage of endometriosis. We used Spearman test to see whether any correlation exists between gene expression (mRNA level) and the stage of disease (from I to IV) and found no significant correlations.
When we compared expression of genes between infertile and fertile individuals, we found that within the endometriosis group there are no significant differences. We found, however, that expression of 4EPB1 and AKT1 was significantly higher in control endometrium collected from the infertile patients than in the fertile controls (P ¼ 0.01 for both genes). It is also of note that expression of 4EBP1 and AKT1 was significantly higher in the endometrium of infertile subgroup of patients with endometriosis versus the infertile controls (P ¼ 0.04 and P ¼ 0.04, respectively) as well as between endometrium from fertile subgroup of women with endometriosis versus fertile controls (P ¼ 0.04 and P ¼ 0.01, respectively). Details of RQ values for all genes in relation to fertility status of patients are presented in 
Localization of 4EPB1 and AKT1 in endometrium
Immunoreactivity for 4EBP1 was observed in about 10% of the endometrial glandular nuclei and to a lesser extent (about 2%) in stromal nuclei (Fig. 4A ). In the cytoplasm of glandular and endothelial cells, the staining for 4EBP1 was observed faintly and diffusely. In contrast, AKT1 immunoreactivity was observed in virtually 100% of glandular cell cytoplasm and in about 60-70% of stromal cytoplasms (Fig. 4B) . Punctuate endothelial cytoplasmatic reaction could also be observed for both 4EBP1 and AKT1. We analyzed the immunolocalization patterns in endometrial sections from women with and without endometriosis. In every case, regardless of whether the endometrium was from women with or without endometriosis, AKT1 and 4EBP1 presented virtually the same number of immunopositive cells as well as typical (as described above) cellular localization of staining (data not shown).
Discussion
In our study we demonstrated for the first time that mRNA levels of 4EBP1 and AKT1 are increased in the eutopic endometria of women with endometriosis as compared with the control group. We also found that only 4EBP1 mRNA levels (from 15 genes studied) are significantly higher in the eutopic endometrium than in ovarian endometriosis collected from the same patients. Similar results were found between the ovarian lesions and the control endometrium, collected from the patients without endometriosis, in that most of genes were found to be up-regulated in the ovarian lesion group, apart from TSC2 and 4EBP1. Despite very scant knowledge of the roles AKT1 and 4EBP1 might play in the development of endometriosis, both genes and their protein products are known to affect different cellular pathophysiological processes. AKT, also known as protein kinase B, regulates various cellular processes, including cell growth, apoptosis and glycogen synthesis, that eventually may lead to reduced cell adhesion, increased motility and invasiveness, common features of cancer and endometriosis (Ness, 2003; Bellacosa et al., 2005) .
4EBP1 is, on the other hand, a crucial TSG which was proposed as a central factor upon which diverse oncogenic signals may converge (Castellvi et al., 2006; Rice et al., 2006) . It plays a critical role in controlling ribosome protein synthesis, and hence, in cell survival and proliferation. Recent experimental studies have shown that 4EBP1 has a central role in cell transformation, and conversely, when it is inactivated, a reversion of the transformed phenotype is observed (Castellvi et al., 2006; Rice et al., 2006) .
Although no study has so far concentrated on the gene expression level of both AKT1 and 4EBP1 in the endometrium of women with endometriosis, there are some interesting data showing a potential role of AKT1 in the pathophysiology of endometrium. There was found an overexpression of insulin-like growth factor I receptor and downstream activation of AKT in endometrial hyperplasia and carcinoma as compared with normal endometrium, and this was accompanied by loss of PTEN expression (McCampbell et al., 2006) . Elevated phospho-AKT was also detected in ovarian cancer versus endometriosis specimens from premenopausal women and endometriosis specimens from postmenopausal women (Yagyu et al., 2006) . In the same study elevated phospho-mTOR was detected in ovarian cancer, and in postmenopausal endometriosis versus premenopausal endometriosis. The difference in expression of mTOR between pre-and post-menopausal endometriosis is explained by the fact that some endometriosis specimens obtained from post-menopausal women are clearly different from those obtained from premenopausal women, in that the activity and level of mTOR increase with age (Yagyu et al., 2006) . In our study we used only premonopausal samples and no difference in mTOR mRNA levels between endometrium of women with and without endometriosis was observed.
The main downstream effector of the AKT1 pathway is 4EBP1 which is frequently overexpressed in different carcinomas, particularly those in the ovary and breast (Castellvi et al., 2006; Rice et al., 2006) . In ovarian cancer 4EBP1 was independently associated with poor prognosis, regardless of other oncogenic pathways, including even AKT1 (Castellvi et al., 2006; Rice et al., 2006) .
We found that AKT1 and 4EBP1 proteins are present in the endometria of women with and without endometriosis, however, we observed no differences in expression pattern between the two groups of patients. The finding that there is no difference in immunostaining between the controls and cases despite the difference in mRNA abundance (higher mRNA levels of both genes in women with endometriosis) may be explained by possible post-transcriptional inhibition and alterations in protein conformation resulting from unknown mutations or effects of phoshporylation -dephosphorylation status. This hypothesis is supported further by detailed reports discussing both transcriptional and translational regulation of AKT1 and 4EBP1 (Hanada et al., 2004; Inoki et al., 2005b) .
The reason why the mRNA levels of AKT1 and 4EBP1 are higher in eutopic endometrium of women with minimal and mild endometriosis as compared with moderate and severe disease is unknown. It is commonly accepted that endometriotic lesions from earlier stages show more extensive biological activity, in terms of different growthstimulating factors, such as those involved in the plasminogen activator-inhibitor system (Gilabert-Estelles et al., 2003) . Our results might also allow us to speculate that higher levels of AKT1 and 4EBP1 mRNAs in the eutopic endometrium could contribute to, or result from, an elevated biological activity in the initial stages of endometriosis as compared with advanced disease. It is feasible that changes in the expression of these genes might lead to, or be a consequence of, an early defect in the physiological activity of endometrium, ultimately resulting in its overgrowth outside uterus. On the other hand, our results may be partly complicated by some inherent drawbacks of our study which need to be discussed. First drawback concerns efficiency and adequacy in the collection of endometriosis samples, particularly those from the ovary. We attempted to collect all visible foci from the surfaces of peritoneum as well as endometrial cysts from ovaries, and immediately after collection placed them separately in RNA conserving liquid and buffered formalin for histopathology. After RNA isolation and assessment of its integrity (by RIN value) we found that only in 17 of 40 patients with visible endometriosis were we able to obtain RNA that barely fulfilled the acceptable criteria of at least 'seven' points, with relatively clearly visible bands. In contrast, the median RIN values of endometrium from women both with and without endometriosis were about 'nine' and the bands were, in every case, particularly clear (data not shown). This, in our view, undoubtedly points to reduced degradation of these samples. Surprisingly, however, we found that mRNA levels for most genes (apart from TSC2 and AKT1 which did not differ, and 4EBP1 which showed lower levels) was significantly higher in endometriosis lesions than in matched endometrium. The results suggest, that despite RNA degradation in endometriotic lesions, in most of the cases there was higher absolute expression of the studied tumor suppressor and oncogenes. It is important to keep in mind that this may not necessarily point to their potential role in this type of tissue and to test this further the laser-captured microdissection is recommended. This technique is currently being introduced in our laboratory in order to ensure the most accurate sample selection.
Another drawback may concern the structure of the control group, which is limited to infertile patients, and showing simple ovarian cysts. It is therefore difficult to evaluate whether the control group is indeed appropriate, since infertility and cysts themselves might to some degree influence expression of genes in endometrium. We believe, however, that any effects in relation to TSGs and oncogenes should not be as profound as for other environmentally labile, inflammationrelated cytokines that are known to affect the course of infertility and/or pain (Gupta et al., 2008) . In addition, it is important to mention that in Poland it is impossible to collect the most suitable healthy control samples in endometriosis research (endometrium, peritoneal fluid etc.), such as those taken during sterilization, as this procedure is an illegal form of contraception. Interestingly, we found that 4EPB1 and AKT1 mRNA levels were significantly higher in the control endometrium from infertile patients than in fertile controls, which would suggest that infertility may somehow positively influence expression of these genes. However, we also showed that 4EPB1 and AKT1 mRNA levels are significantly higher in the endometriosis group of patients regardless of fertility status, which seems to add to uncertainties about the role of endometriosis in infertility. It is also difficult to comment on the correlation between expression of some genes, for example P53 and PTEN, and cycle day as we limited our patients to only 5 days of the proliferative phase (day 8-12), the time when a great majority of patients are operated on in our Department. Patient operations were randomly allocated to a given day of the cycle, giving only two and six patients with endometriosis for cycle days 10 and 11, respectively. We believe that the analysis would be better founded if more patients were recruited and all were sampled on one designated day of the cycle.
Based on our results we speculate that both 4EBP1 and AKT1 could facilitate the subsequent abnormal growth outside the uterus and might be an important clue to the pathogenesis of endometriosis. In this paper we investigated the expression profile for one of the most important gene pathways and we believe that the results pave the way for more functional studies that are needed to elucidate a possible role in endometriosis. 
